2Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B [ J ]. Hepatology, 2000,31 : 207 - 210. 被引量：1
3Liaw YF, Sung J J, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351:1521 -1531. 被引量：1
4Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection[J]. Gastrenterology, 2002, 123:1831 - 1838. 被引量：1
2Lewin S, Walters T, Locarnini S. Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. Antivir Res,2002,55: 381-396. 被引量：1
3Schneller SW. Carbocylic nucleosides (carbonucleosides) as new therapeutic leads. Curr Top Med Chem,2002:1087-1092. 被引量：1
4Marion PL, Salazar FH, Winters MA, et al. Potent effecacy of entecavir(BMS-200475) in a duck model of hepatitis B virus infection. Antimicrob Agents Chemother, 2002,46:82-88. 被引量：1
5Yamanaka G. Metabolic studies on BMS-200475,a new conpound active against hepatits B virus. Antimicrob Agents Chemother, 1999,43:190-193. 被引量：1
6Levine S. Efficacies of entecavir ngainst lamivudine-resistant hepatitis B virus replication and recombinatant polymerases in vitro. Antimicrob Agents Chemother, 2002,46: 2525-2532. 被引量：1
7Bifano M. Hepatic impairment does not alter single-does pharmacokinetics and safety of entecavir. Hepatology, 2004,40: ( 4 suppl. 1 ): 1149. 被引量：1
8Wolters LM, Hansen BE, Niesters HE, et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol,2002,37:137-144. 被引量：1
9Chang T. Sustained viral load and ALT reduction following 49 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine.Hepatology, 2002,36. 被引量：1
10Schiff ER. Entecavir 1.0 mg is consistently superior to lamivudine at 48 weeks across multiple baseline HBV disease characteristics in lamivudine refractory patients. Hepatology, 2004,40:(4 suppl. 1): 131. 被引量：1
5Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
7Gish R G,Lok A S,Chang T T,et al. Entecavir Therapy for up to 96 Weeks in Patients with HBeAg-positive Chronic Hepa-titis B[J]. Gastroenterology, 2007,133 (5) : 1437-1444. 被引量：1
8[2]Perrillo RP,Wrihgt T,Rakela J,et al.A multicenter United States-Canadian trail to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B[J].Hepatology,2001,33(2):424-432. 被引量：1
9[3]Hann HW,Fontana RJ,Wright T,et al.A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis[J].Liver Transpl,2003,9(1):49-56. 被引量：1
10[6]Forman LM,Lucey MR.Predicting the prognosis of chronic liver disease:an evolution from child to MELD.Mayo End-stage Liver Disease[J].Hepatology,2001,33(2):473-475. 被引量：1
